Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The mechanistic target of rapamycin (mTOR) pathway is crucial in cell growth and survival.
• mTOR complex 2 (mTORC2) is typically considered rapamycin-insensitive and regulates the AKT kinase.
• Acute myeloid leukemia (AML) is a hematologic malignancy with complex signaling pathways.

Purpose of the Study:

• To investigate the molecular effects of rapamycin derivatives (RDs) on mTOR signaling in AML cells.
• To determine if RDs can inhibit mTORC2 and its downstream targets in AML.
• To evaluate the therapeutic potential of mTOR inhibition in leukemias.

Main Methods:

• Treatment of AML cell lines with temsirolimus and everolimus.
• Analysis of mTORC1 and mTORC2 signaling components (e.g., p70S6K, 4EBP1, AKT, FKHR phosphorylation).
• Assessment of gene expression (e.g., GLUT1, D-cyclins) and evaluation in patient samples.

Main Results:

• RDs inhibited both mTORC1 and mTORC2 formation and activity in AML cells.
• RDs suppressed AKT phosphorylation at Ser473 and its downstream substrate FKHR.
• Decreased transcription of D-cyclins and GLUT1 was observed, along with similar effects in patient samples.

Conclusions:

• Rapamycin derivatives demonstrate potent inhibition of AKT signaling in primary AML cells, both in vitro and in vivo.
• This study provides the first evidence of RDs inhibiting mTORC2 in AML.
• mTOR inhibition represents a promising therapeutic strategy for hematologic malignancies like AML.